2Ross R. Atherosclerosis- An inflammatory disease. N Eng J Med,1999,340:115 - 126.
3Pascer V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C - reactive protein on human endothelial cells. Circulation,2000,102:2165-2168.
4Pascer V, Chang J, Willerson JT, et al. Modulation of C - reactive protein mediated monocyte chemoattractant protein - 1 induction in human endothelial cells by anti - atherosclerosis drugs. Circulation, 2001,103 :2531 - 2534.
5Mallat Z,Corbaz A,Scoazec A, et al. Expression of interleukin - 18 in human atherosclerosis plaque instability. Circulation,2001,104:1598- 1063.
6Stefanadis C, Toutouzas K, Taiamis E, et al. Increased local temperature in human coronary atherosclerotic plaques: An independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention. J Am Coll Cardiol, 2001,37:1277- 1283.
7Hermann A, Rauch BH, Braun M, et al. Platelet CD40 ligand(CD4OL): subcellular localization, regulation of expression and inhibition by clopidogrel. Platelets, 2001, ; 12:74 - 82.
8Malik J, Melenovsky V, Wichterle D, et al. Both fenoflbriate and atorvastatin improve vascular reactivity in combined hyperlipdaemia( Fenofibriate Venus Atorvastatin Trial - FAT ). Cardiovac Res, 2001,52: 290 -298.
9Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammarion in vitro and in vivo by peroxisome proliferator - activated receptor - gamma activators. Circulation,2000, ; 101:235 - 238.
9Yokoyama S,Ikeda H,Haramaki N,et al.HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmen-ting platelet-deriveb nitric oxide release in rats[J]. Cardiovasc Pharmacol,2005,45:375-381.
10Buemi M,Nostro L,Crasci E,et al.Statins in nephrotic syndrome:a new weapon against tissue injury[J].Med Res Rev,2005,25:587-489.
